Rupert Vessey, Bristol Myers Squibb's President of Research and Early Development
May 10, 2022 12:37 PM EDTUpdated May 11, 03:34 AM
Deals

Pro­tein degra­da­tion field turns red hot as Bris­tol My­ers signs up for an­oth­er multi­bil­lion-dol­lar pact

John Carroll

Editor & Founder

A new sea­son of pro­tein degra­da­tion deals is up­on us.

Just days af­ter Ru­pert Vessey an­ted up on a $1.55 bil­lion deal to ad­vance new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times